 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...888990919293949596979899100 |
- ||| Trial initiation date: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy (clinicaltrials.gov) - Jul 5, 2012
P2, N=300, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Feb 2011 --> Aug 2011
- ||| Ibrance (palbociclib) / Pfizer
Enrollment change, Metastases: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Jun 21, 2012
P1/2, N=177, Active, not recruiting, Sponsor: Pfizer
Initiation date: Feb 2011 --> Aug 2011 N=225 --> 177
- ||| lapatinib / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Trial initiation date, Combination therapy, Metastases: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer (clinicaltrials.gov) - Jun 11, 2012
P2, N=76, Recruiting, Sponsor: University of Maryland
N=225 --> 177 Initiation date: Jan 2012 --> May 2012
- |||| lapatinib / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open, Combination therapy, Metastases: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer (clinicaltrials.gov) - Jun 11, 2012
P2, N=76, Recruiting, Sponsor: University of Maryland
Initiation date: Jan 2012 --> May 2012 Not yet recruiting --> Recruiting
- lapatinib / Generic mfg., letrozole / Generic mfg.
Trial termination, Combination therapy: PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE (clinicaltrials.gov) - Jun 6, 2012
P2, N=6, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; slow accrual
- letrozole / Generic mfg.
Enrollment open: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Jun 5, 2012
P2, N=115, Recruiting, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Terminated; slow accrual Not yet recruiting --> Recruiting
- Biomarker, New P4 trial: MIRHO: Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer (clinicaltrials.gov) - Jun 4, 2012
P4, N=39, Recruiting, Sponsor: Institut Claudius Regaud
- Herceptin (trastuzumab) / Roche
Enrollment change, Monotherapy: SAKK 23/03: Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer (clinicaltrials.gov) - Jun 3, 2012
P2, N=13, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Not yet recruiting --> Recruiting N=40 --> 13
- letrozole / Generic mfg.
New P2 trial: Randomized Study of Letrozole and Trilostane for Medical Abortion (clinicaltrials.gov) - Jun 3, 2012
P2, N=36, Recruiting, Sponsor: Kristina Gemzell Danielsson
- Herceptin (trastuzumab) / Roche
Trial completion, Monotherapy: SAKK 23/03: Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer (clinicaltrials.gov) - Jun 3, 2012
P2, N=13, Completed, Sponsor: Swiss Group for Clinical Cancer Research
N=40 --> 13 Active, not recruiting --> Completed
- letrozole / Generic mfg.
Trial withdrawal, Metastases: Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 30, 2012
P3, N=0, Withdrawn, Sponsor: Technische Universit
Active, not recruiting --> Completed Recruiting --> Withdrawn
- letrozole / Generic mfg.
Enrollment change, Metastases: Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 30, 2012
P3, N=0, Withdrawn, Sponsor: Technische Universit
Recruiting --> Withdrawn N=1500 --> 0
- capecitabine / Generic mfg.
Trial termination, Metastases: Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer (clinicaltrials.gov) - May 9, 2012
P2/3, N=10, Terminated, Sponsor: The Netherlands Cancer Institute
N=1500 --> 0 Recruiting --> Terminated; acrual too slow
- capecitabine / Generic mfg.
Enrollment change, Metastases: Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer (clinicaltrials.gov) - May 9, 2012
P2/3, N=10, Terminated, Sponsor: The Netherlands Cancer Institute
Recruiting --> Terminated; acrual too slow N=128 --> 10
- | letrozole / Generic mfg.
Trial completion, Monotherapy, Metastases: Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment (clinicaltrials.gov) - May 8, 2012
P2, N=47, Completed, Sponsor: Novartis Pharmaceuticals
N=128 --> 10 Active, not recruiting --> Completed
- | metformin / Generic mfg., letrozole / Generic mfg.
New P2 trial: Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer (clinicaltrials.gov) - Apr 29, 2012
P2, N=208, Recruiting, Sponsor: Seoul National University Hospital
- letrozole / Generic mfg.
Enrollment closed: Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients (clinicaltrials.gov) - Apr 24, 2012
P=N/A, N=100, Active, not recruiting, Sponsor: New York Medical College
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | letrozole / Generic mfg.
Enrollment change, Metastases: A Study of Letrozole in the Treatment of Endometrial Cancer (clinicaltrials.gov) - Apr 17, 2012
P2, N=36, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=30 --> 36
- | letrozole / Generic mfg.
Enrollment change: Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer (clinicaltrials.gov) - Apr 17, 2012
P2, N=17, Completed, Sponsor: Novartis Pharmaceuticals
N=30 --> 36 N=30 --> 17
- letrozole / Generic mfg.
Enrollment change: Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment (clinicaltrials.gov) - Apr 17, 2012
P4, N=13, Terminated, Sponsor: Novartis Pharmaceuticals
N=30 --> 17 N=210 --> 13
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
New P3 trial: The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) (clinicaltrials.gov) - Apr 11, 2012
P3, N=150, Completed, Sponsor: Nik Hazlina
- Bosulif (bosutinib) / Pfizer
Trial termination, Combination therapy, Metastases: Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer (clinicaltrials.gov) - Mar 28, 2012
P2, N=16, Terminated, Sponsor: Pfizer
N=210 --> 13 Completed --> Terminated; See termination reason in detailed description.
- tamoxifen / Generic mfg.
New P4 trial: OXYTAM: Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not (clinicaltrials.gov) - Mar 12, 2012
P4, N=29, Completed, Sponsor: Institut Claudius Regaud
- Cetrotide (cetrorelix) / EMD Serono, Lutrelef (gonadorelin acetate) / Ferring
Enrollment closed: Reproductive Hormonal Alterations in Obesity (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=60, Active, not recruiting, Sponsor: University of Colorado, Denver
Completed --> Terminated; See termination reason in detailed description. Recruiting --> Active, not recruiting
- letrozole / Generic mfg.
Trial initiation date: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Feb 15, 2012
P2, N=115, Recruiting, Sponsor: Cancer and Leukemia Group B
Recruiting --> Active, not recruiting Initiation date: Oct 2011 --> Feb 2012
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment change: Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - Jan 25, 2012
P2, N=51, Completed, Sponsor: University of Maryland
Initiation date: Oct 2011 --> Feb 2012 N=100 --> 51
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion: Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - Jan 25, 2012
P2, N=51, Completed, Sponsor: University of Maryland
N=100 --> 51 Recruiting --> Completed
- ||||| lapatinib / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial, Combination therapy, Metastases: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer (clinicaltrials.gov) - Dec 22, 2011
P2, N=76, Recruiting, Sponsor: University of Maryland
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment closed, Surgery: Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Dec 22, 2011
P3, N=610, Active, not recruiting, Sponsor: American College of Surgeons
Recruiting --> Completed Suspended --> Active, not recruiting
- ||||| letrozole / Generic mfg., zoledronic acid / Generic mfg.
Enrollment closed, Surgery: FEMZONE: Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer (clinicaltrials.gov) - Dec 20, 2011
P2/3, N=168, Active, not recruiting, Sponsor: Novartis
Suspended --> Active, not recruiting Completed --> Active, not recruiting
- letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion: Anastrozole and Letrozole (clinicaltrials.gov) - Dec 13, 2011
P=N/A, N=25, Completed, Sponsor: University of Connecticut Health Center
Completed --> Active, not recruiting Active, not recruiting --> Completed
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Dec 8, 2011
P2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- letrozole / Generic mfg., anastrozole / Generic mfg.
Enrollment change: Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy (clinicaltrials.gov) - Nov 30, 2011
P=N/A, N=72, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting N=50 --> 72
- | dovitinib (TKI258) / Novartis, Oncoheroes
New P1/2 trial, Combination therapy, Metastases: Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer (clinicaltrials.gov) - Nov 30, 2011
P1/2, N=36, Recruiting, Sponsor: Georgetown University
- letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion: Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy (clinicaltrials.gov) - Nov 30, 2011
P=N/A, N=72, Completed, Sponsor: City of Hope Medical Center
N=50 --> 72 Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Nov 1, 2011
P2, N=50, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Mifeprex (mifepristone) / Danco Laboratories
Clinical: Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy (clinicaltrials.gov) - Oct 30, 2011
P=N/A, N=50, Recruiting, Sponsor: The University of Hong Kong
- Herceptin (trastuzumab) / Roche
Enrollment change: HELEX: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy (clinicaltrials.gov) - Oct 26, 2011
P2, N=96, Recruiting, Sponsor: Baylor Breast Care Center
Active, not recruiting --> Completed N=55 --> 96
- Herceptin (trastuzumab) / Roche
Enrollment open: HELEX: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy (clinicaltrials.gov) - Oct 26, 2011
P2, N=96, Recruiting, Sponsor: Baylor Breast Care Center
N=55 --> 96 Not yet recruiting --> Recruiting
- letrozole / Generic mfg.
Enrollment closed, Metastases: Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma (clinicaltrials.gov) - Oct 25, 2011
P2, N=37, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy, Monotherapy, Metastases: Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women (clinicaltrials.gov) - Oct 24, 2011
P3, N=378, Active, not recruiting, Sponsor: Spanish Breast Cancer Research Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca. (clinicaltrials.gov) - Sep 25, 2011
P2, N=30, Completed, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | letrozole / Generic mfg.
New P2 trial: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Sep 21, 2011
P2, N=115, Recruiting, Sponsor: Cancer and Leukemia Group B
- ||||||| letrozole / Generic mfg.
Trial completion, Surgery: Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Sep 21, 2011
P3, N=300, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- letrozole / Generic mfg.
Enrollment change: Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density (clinicaltrials.gov) - Sep 12, 2011
P2, N=68, Completed, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed N=120 --> 68
- letrozole / Generic mfg.
Clinical: Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Sep 7, 2011
P=N/A, N=420, Recruiting, Sponsor: Heilongjiang University of Chinese Medicine
- PF-04691502 / Pfizer
New P2 trial, Combination therapy, IO biomarker: Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer (clinicaltrials.gov) - Sep 6, 2011
P2, N=14, Terminated, Sponsor: Pfizer
- | Decuprate (bis-choline tetrathiomolybdate) / AstraZeneca
New P2 trial, Combination therapy: A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with letrozole versus letrozole alone in post-menopausal women with recurrent, oestrogen and/or progesterone receptor positive breast cancer (EUDRACT) - Aug 21, 2011
P2, N=111, Ongoing, Sponsor: Cancer Research UK
- | letrozole / Generic mfg., zoledronic acid / Generic mfg.
Trial completion: Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole (clinicaltrials.gov) - Aug 21, 2011
P3, N=90, Completed, Sponsor: Soroka University Medical Center
N=120 --> 68 Recruiting --> Completed
- letrozole / Generic mfg.
Trial completion: Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer (clinicaltrials.gov) - Aug 9, 2011
P2, N=100, Completed, Sponsor: University of Washington
Recruiting --> Completed Active, not recruiting --> Completed